INTT vs RARE · P/E 444, rev $33.9M vs rev $350.0M
inTest Corporation (INTT) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
inTest Corporation (INTT) is a semiconductor equipment & materials company listed on AMEX.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported INTT revenue for 2026-03-31 was $33.9M. Net income was $789.0K. Revenue was down 58.2% from 2025-09-30 to 2026-03-31. INTT currently screens at market cap $223.3M and trailing P/E 444.3.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
INTT currently screens at market cap $223.3M and trailing P/E 444.3. RARE currently screens at market cap $2.79B.
Not investment advice. Open the INTT and RARE stock pages for the full models.
Not investment advice.